Fig 1.
Flow diagram of patient inclusion and exclusion process.
Table 1.
Diagnostic efficacy of FAPI-PET for breast cancer.
Fig 2.
Al¹⁸F-NOTA-FAPI-04 PET/CT images of a 38-year-old female patient with breast invasive ductal carcinoma (molecular subtype: LuminalB).
(A) Whole-body maximum-intensity projection (MIP) image shows multiple FAPI-avid lesions. Solid thick arrows in axial PET (B), CT (C), and fused PET/CT (D) images indicate the primary breast tumor. Open thick arrows in axial PET (E), CT (F), and fused PET/CT (G) images denote supraclavicular lymph node metastases. Thin arrows in axial PET (H), CT (I), and fused PET/CT (J) images indicate axillary lymph node metastases. Triangles in axial PET (K), CT (L), and fused PET/CT (M) images indicate an internal mammary lymph node. Open arrowheads in axial PET (N), CT (O), and fused PET/CT (P) images indicate a hepatic metastasis.
Fig 3.
Al¹⁸F-NOTA-FAPI-04 PET/CT images of a 50-year-old female patient with breast mucinous carcinoma (molecular subtype: HER2-positive).
(A) Whole-body maximum-intensity projection (MIP) image reveals a mildly FAPI-avid lesion (low to moderate tracer uptake) in the right breast. Solid thick arrows in axial PET (B), CT (C), and fused PET/CT (D) images localize the primary tumor (mucinous carcinoma, a subtype with indolent biology), which exhibits low tracer uptake (consistent with the subtype’s relatively low cancer-associated fibroblast infiltration).
Table 2.
Comparison of uptake parameters of primary lesions among different pathological types of breast cancer.
Table 3.
Comparison of uptake parameters of primary lesions among breast cancer patients with different immunohistochemical features.
Table 4.
Comparison of uptake parameters of primary lesions among different molecular subtypes of breast cancer.